Results 1 to 10 of about 101,548 (353)

Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy

Journal of Diabetes Investigation, 2023
Aims/Introduction Previous studies have reported that the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) delays gastric emptying, and gastric emptying was assessed by the 13C breath test or paracetamol absorption technique.
Toshiko Kobori, Yukiko Onishi, Yoko Yoshida, Tazu Tahara, Takako Kikuchi, Tetsuya Kubota, Masahiko Iwamoto, Tomonobu Sawada, Reo Kobayashi, Hiroaki Fujiwara, Masato Kasuga   +10 more
doaj   +2 more sources

Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy

Journal of Cachexia, Sarcopenia and Muscle, 2019
Background Skeletal muscle atrophy is defined as a reduction of muscle mass caused by excessive protein degradation. However, the development of therapeutic interventions is still in an early stage.
Yeonhee Hong, Jong Han Lee, Kwang Won Jeong, Cheol Soo Choi, Hee‐Sook Jun   +4 more
doaj   +2 more sources

Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis. [PDF]

Anaesthesia
Glucagon‐like peptide‐1 receptor agonists are known to delay gastric emptying; however, the association between glucagon‐like peptide‐1 receptor agonist use and peri‐operative pulmonary aspiration risk is not known.
Elkin J, Rele S, Sumithran P, Hii M, Thuraisingam S, Spelman T, Phan T, Choong P, Dowsey M, Shadbolt C.   +9 more
europepmc   +2 more sources

Suspected liraglutide (glucagon-like peptide-1 receptor agonist)-induced hyperthyroidism: A case report [PDF]

Malaysian Family Physician
Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is widely used for weight management and glycaemic control. While generally well-tolerated, various adverse effects have been reported. Thyroid dysfunction, particularly hyperthyroidism,
Siti Nur Syakinah Md Sabudin, Lili Husniati Yaacob, Muhammad Rahmat Che Omar   +2 more
doaj   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis

Frontiers in Endocrinology, 2021
ObjectiveNon-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite
Chloe Wong, Ming Hui Lee, Clyve Yu Leon Yaow, Yip Han Chin, Xin Lei Goh, Cheng Han Ng, Amanda Yuan Ling Lim, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Chin Meng Khoo, Chin Meng Khoo   +12 more
doaj   +1 more source

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.

JAMA Internal Medicine, 2022
Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been widely recommended for glucose control and cardiovascular risk reduction in patients with type 2 diabetes, and more recently, for weight loss.
Liyun He, Jialu Wang, F. Ping, N. Yang, Jingyue Huang, Yuxiu Li, Lingling Xu, Wei Li, Huabing Zhang   +8 more
semanticscholar   +1 more source

Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation [PDF]

, 2016
The glucagon-like peptide receptor (GLP-1R), which is a G-protein coupled receptor (GPCR), signals through both Gαs and Gαq coupled pathways and ERK phosphorylation to stimulate insulin secretion.
A Bond, A Thompson, A Thompson, A Thompson, A Thompson, AC Hanyaloglu, Aiysha Thompson, B Thorens, BD Green, C Koole, C Montrose-Rafizadeh, C Orskov, CE Groer, CR Underwood, D Wootten, D Wootten, DJ Drucker, FS Willard, FS Willard, GG Holz, JC Davies, JC Davies, Jeffrey W. Stephens, JT Patterson, K Coopman, K Venkateswarlu, K Zahn, KW Sloop, L Ma, LB Knudsen, M Edavalath, ME Doyle, MR Price, N Irwin, N Li, P Vazquez, R Goke, R López de Maturana, Rasheed Ahmad, RL Thomas, RS Kuna, S Takhar, SK Mathi, SN Roed, Stephen C. Bain, T Kim Chung le, TM Bridges, TP Vahl, V Kanamarlapudi, V Serre, Venkateswarlu Kanamarlapudi, WM Nolte, YH Cheong   +52 more
core   +13 more sources

Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US

JAMA Health Forum, 2021
Key Points Question Are there inequities in glucagon-like peptide-1 receptor agonist (GLP-1 RA) use based on race, ethnicity, sex, and socioeconomic status among patients with diabetes in the US?
L. Eberly, Lin Yang, U. Essien, N. Eneanya, H. Julien, Jing Luo, Ashwin S. Nathan, S. Khatana, E. Dayoub, Alexander C. Fanaroff, Jay S Giri, P. Groeneveld, S. Adusumalli   +12 more
semanticscholar   +1 more source

Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes

JAMA Network Open, 2023
Key Points Question Among adults with type 2 diabetes (T2D), what is the efficacy, safety, and tolerability of the novel, orally administered, small molecule glucagon-like peptide 1 receptor agonist danuglipron?
A. Saxena, J. Frias, Lisa S. Brown, Donal N. Gorman, Szilárd Vasas, N. Tsamandouras, M. Birnbaum   +6 more
semanticscholar   +1 more source

Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner

Communications Biology, 2021
Li, Chen, Vong, Zhao et al. show that glucagon-like peptide-1 receptor agonist reverses transcriptomic aging signatures in mouse glial and neurovascular cells.
Zhongqi Li, Xinyi Chen, Joaquim S. L. Vong, Lei Zhao, Junzhe Huang, Leo Y. C. Yan, Bonaventure Ip, Yun Kwok Wing, Hei-Ming Lai, Vincent C. T. Mok, Ho Ko   +10 more
doaj   +1 more source